FRONTIER-AD
Research type
Research Study
Full title
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis
IRAS ID
280132
Contact name
Sarah McFarlane
Contact email
Sponsor organisation
AstraZeneca AB
Eudract number
2019-003304-12
Clinicaltrials.gov Identifier
141236, IND number
Duration of Study in the UK
1 years, 1 months, 26 days
Research summary
AstraZeneca AB is doing this research to find out if an experimental medication called MEDI3506 works and is safe for the treatment of atopic dermatitis. MEDI3506 is an experimental medication because it has not been fully tested. It has not been approved by any health authority, except for use in research studies like this.
MEDI3506 is an artificial (laboratory-made) human antibody that binds to and blocks the actions of a natural substance found in the body called interleukin-33 (IL-33). Antibodies are proteins that are naturally produced by the body’s defense system. Since IL-33 is involved in chronic inflammatory conditions such as atopic dermatitis, it is anticipated that MEDI3506 will reduce the symptoms of atopic dermatitis.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
20/EE/0156
Date of REC Opinion
25 Jun 2020
REC opinion
Favourable Opinion